AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.505

-0.015-2.88%

Volume:130.78K

Turnover:66.59K

Market Cap:109.84M

PE:-4.54

High:0.520

Open:0.520

Low:0.500

Close:0.520

52wk High:0.785

52wk Low:0.350

Shares:217.51M

Float Shares:149.50M

Volume Ratio:0.26

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.111

EPS(LYR):-0.095

ROE:-54.98%

ROA:-31.75%

PB:2.57

PE(LYR):-5.32

Loading ...

Overview Company News Filings

Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options

MT Newswires Live

Alterity Therapeutics Limited-$4.2M Options Underwriting Agreement Executed

THOMSON REUTERS

Alterity Therapeutics FY26 Net Loss Widens to $23.4 Million; R&D Expenses Rise 22% to A$17.63 Million

Alterity Therapeutics Limited-Disclosure Under Takeovers Panel Gn 20

THOMSON REUTERS

Alterity Wins New US Composition-of-Matter Patent for Ath434, Extending Protection to 2045

Alterity Therapeutics Secures New Patent for Oral Drug Candidate for Neurodegenerative Diseases; Shares Up 7%

MT Newswires Live

Alterity Therapeutics Limited-Granted New U.S. Composition of Matter Patent for Ath434

THOMSON REUTERS

Alterity Therapeutics CEO Presents at Canaccord Genuity Growth Conference

Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government

MT Newswires Live

Alterity Says FDA Backs Single Phase 3 Trial Path to Potential Ath434 Approval in Multiple System Atrophy

Alterity Therapeutics: FDA Agreed a Single Pivotal Phase 3 Trial Plus Confirmatory Evidence Could Support Approval of Ath434 for Treatment of MSA

THOMSON REUTERS

Alterity Therapeutics: Pivotal Phase 3 Trial Activities on Track to Initiate by Year-end 2026

THOMSON REUTERS

Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%

MT Newswires Live

Alterity Therapeutics Ltd-fda Meeting Minutes Confirm Registrational Path for Ath434

THOMSON REUTERS

Here's Why We're Not Too Worried About Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

Simply Wall St.

BRIEF-Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy

Alterity Therapeutics - FDA Agrees to Phase 3 Design Including Umsars Part I as Primary Endpoint

THOMSON REUTERS

Alterity Therapeutics - FDA Concurs With Ath434 50 Mg Twice Daily Dose for Phase 3

THOMSON REUTERS

Alterity Therapeutics - Phase 3 Trial Activities on Track to Initiate by Year-End 2026

THOMSON REUTERS

Alterity Therapeutics Ltd-Alterity and FDA Agree on Phase 3 Program for Ath434 in MSA-Ath

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ATH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.505,"timestamp":1788156720000,"preClose":0.52,"halted":0,"volume":130784,"delay":0,"changeRate":-0.028846153846153872,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"Not Yet Opened","change":-0.015,"latestTime":"08-31 16:12:00 AEST","open":0.52,"high":0.52,"low":0.5,"amount":66588,"amplitude":0.038462,"askPrice":0.52,"askSize":3795,"bidPrice":0.505,"bidSize":17233,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.52,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.25804,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.52,"auctionPrice":0.505,"auctionVolume":13229,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156595015}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-31.75%","roe":"-54.98%","lyrEps":-0.09495,"volumeRatio":0.25804,"shares":217508326,"dividePrice":0,"high":0.52,"amplitude":0.038462,"preClose":0.52,"low":0.5,"week52Low":0.35,"pbRate":"2.57","psRate":"20.62","week52High":0.785,"institutionHeld":0,"latestPrice":0.505,"committee":0.639053,"eps":-0.1112,"divideRate":0,"volume":130784,"delay":0,"ttmEps":-0.1112,"open":0.52,"prevYearClose":0.4,"prevWeekClose":0.52,"prevMonthClose":0.545,"prevQuarterClose":0.575,"fiveDayClose":0.505,"twentyDayClose":0.59,"sixtyDayClose":0.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663602953","title":"Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2663602953","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663602953?lang=en_us&edition=fundamental","pubTime":"2026-08-31 10:44","pubTimestamp":1788144243,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  entered into an underwriting agreement with MST Financial Services, under which MST Financial agreed to underwrite the exercise of up to a total of 8.4 million unexercised ATHO listed options ahead of their expiry, according to a Monday Australian bourse filing.There are currently 15.9 million listed ATHO options on issue, exercisable at AU$0.50 and due to expire on Tuesday. MST Financial agreed to underwrite any shortfall arising from options not exercised by optionholders before the expiry date, up to a maximum of 8.4 million options. It will subscribe, or procure subscriptions, for a corresponding number of new fully paid ordinary shares in the firm.MST Financial will receive an underwriting fee of 7% of the gross proceeds raised from the exercise of options underwritten by it.The options are expected to raise around AU$4.2 million before costs, and the proceeds are expected to support continued late-stage clinical development of its ATH434 candidate in multip","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK4139","ATH.AU","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663702858","title":"Alterity Therapeutics Limited-$4.2M Options Underwriting Agreement Executed","url":"https://stock-news.laohu8.com/highlight/detail?id=2663702858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663702858?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:52","pubTimestamp":1788133923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUE7JBTMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662956930","title":"Alterity Therapeutics FY26 Net Loss Widens to $23.4 Million; R&D Expenses Rise 22% to A$17.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662956930","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662956930?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:16","pubTimestamp":1787922993,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics FY26 net loss widens to $23.4 million; R&D expenses rise 22% to A$17.63 millionAlterity Therapeutics posted a net loss of U.S.$23.4 million, widening from U.S.$12.1 million in the prior year.Operating cash outflow widened to U.S.$22.5 million from U.S.$11.5 million; cash and cash equivalents rose to A$37.32 million.Research and development expenses climbed 22% to A$17.63 million; general and administrative costs jumped 92% to A$10.53 million.Interest income rose to A$1.72 million from A$446,291; other income included A$3.61 million tied to the R&D Tax Incentive.An issued capital consolidation of 50-to-1 took effect on May 29, 2026; unexercised options totaled 66,200,000 at June 30.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL88XH8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660042321","title":"Alterity Therapeutics Limited-Disclosure Under Takeovers Panel Gn 20","url":"https://stock-news.laohu8.com/highlight/detail?id=2660042321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660042321?lang=en_us&edition=fundamental","pubTime":"2026-08-17 12:52","pubTimestamp":1786942379,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUE25CJDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658717119","title":"Alterity Wins New US Composition-of-Matter Patent for Ath434, Extending Protection to 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2658717119","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658717119?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:18","pubTimestamp":1786533501,"startTime":"0","endTime":"0","summary":"Alterity wins new US composition-of-matter patent for ATH434, extending protection to 2045Alterity Therapeutics received a new U.S. composition-of-matter patent covering a crystalline form of ATH434 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL73Z8GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","BCDF","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","ATH.AU","SG9999014013.SGD","BK7067","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658404944","title":"Alterity Therapeutics Secures New Patent for Oral Drug Candidate for Neurodegenerative Diseases; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658404944","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658404944?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:30","pubTimestamp":1786494614,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  secured a new composition-of-matter patent for ATH434, the company's oral drug candidate, from the United States Patent and Trademark Office, according to a Wednesday filing with the Australian bourse.ATH434 is designed to treat neurodegenerative diseases such as multiple system atrophy, Parkinson's disease and related disorders, the filing said.The new patent, which extends protection for ATH434 to at least 2045, provides composition-of-matter protection for a crystalline structure of the mesylate salt form of the drug and protection for methods for treating neurological conditions using it, per the filing.The company's shares surged past 7% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATH.AU","BK7067","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949268","title":"Alterity Therapeutics Limited-Granted New U.S. Composition of Matter Patent for Ath434","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949268?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:37","pubTimestamp":1786487821,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUE2X49WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657826776","title":"Alterity Therapeutics CEO Presents at Canaccord Genuity Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657826776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657826776?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:17","pubTimestamp":1786011421,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics CEO presents at Canaccord Genuity Growth ConferenceAlterity Therapeutics CEO David Stamler will present at the 46th Annual Canaccord Genuity Growth Conference on Aug. 11, 2026 at 1:30 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1x4gdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650467109","title":"Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2650467109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650467109?lang=en_us&edition=fundamental","pubTime":"2026-07-09 14:14","pubTimestamp":1783577646,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  received a research and development tax refund from the Australian government of about AU$4 million for the fiscal year 2025, according to a Thursday filing with the Australian bourse.The tax incentive provides the company with \"important funding\" to support the development of its clinical programs, Alterity said.The company's shares gained 2% on market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VAS.AU","BK4539","IIGF.AU","E200.AU","XJO.AU","XAO.AU","IMLC.AU","IISV.AU","OZF.AU","LENZ","BK4007","BEAR.AU","BK4139","XKO.AU","QRE.AU","ZYAU.AU","STW.AU","OZR.AU","GIVE.AU","BK7067","QFN.AU","BBOZ.AU","DACE.AU","GEAR.AU","ATH.AU","EIGA.AU","IOZ.AU","VAP.AU","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649848969","title":"Alterity Says FDA Backs Single Phase 3 Trial Path to Potential Ath434 Approval in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2649848969","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649848969?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422347,"startTime":"0","endTime":"0","summary":"Alterity says FDA backs single Phase 3 trial path to potential ATH434 approval in multiple system atrophyAlterity Therapeutics received FDA End-of-Phase 2 minutes confirming a registrational pathway f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL3Jdb6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","BCDF","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","ATH.AU","SG9999014013.SGD","BK7067","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649989811","title":"Alterity Therapeutics: FDA Agreed a Single Pivotal Phase 3 Trial Plus Confirmatory Evidence Could Support Approval of Ath434 for Treatment of MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649989811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649989811?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:05","pubTimestamp":1783418727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390H4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649841989","title":"Alterity Therapeutics: Pivotal Phase 3 Trial Activities on Track to Initiate by Year-end 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649841989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649841989?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:05","pubTimestamp":1783418727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390H4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649603144","title":"Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649603144","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649603144?lang=en_us&edition=fundamental","pubTime":"2026-07-07 10:36","pubTimestamp":1783391763,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  said the official meeting minutes from its end-of phase-2 meeting for its ATH434 treatment candidate in multiple system atrophy  from the US Food and Drug Administration  confirmed the key elements of the registrational phase 3 program and the path toward a potential new drug application filing, according to a Tuesday Australian bourse filing.The US FDA agreed with the proposed phase 3 trial design, including the study population, treatment regimen, and efficacy endpoints, per the filing. The study is expected to enroll around 200 participants who will receive 50 milligrams doses of ATH434 or matching placebo twice daily for 12 months.The FDA indicated that a single pivotal trial plus confirmatory evidence could provide the necessary data to support an approval of ATH434 for the treatment of MSA, the company said.Pivotal phase 3 trial activities are on track to start by the end of the year.Alterity Therapeutics' shares fell 4% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATH.AU","BK7067","LU2125909916.SGD","LENZ","LU2125909759.SGD","LU0728928796.USD","LU2211815571.USD","LU0053671581.USD","BK4007","LU0154245756.USD","LU0154245673.USD","BK4143","BK4585","LABU","MSA","LU1815336091.USD","LU0757428866.USD","BK4539","LU1923622291.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649720326","title":"Alterity Therapeutics Ltd-fda Meeting Minutes Confirm Registrational Path for Ath434","url":"https://stock-news.laohu8.com/highlight/detail?id=2649720326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649720326?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:44","pubTimestamp":1783381472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUE4P0JWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644928267","title":"Here's Why We're Not Too Worried About Alterity Therapeutics' (ASX:ATH) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644928267","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644928267?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:14","pubTimestamp":1781651689,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ath/alterity-therapeutics-shares/news/heres-why-were-not-too-worried-about-alterity-therapeutics-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ath/alterity-therapeutics-shares/news/heres-why-were-not-too-worried-about-alterity-therapeutics-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642464254","title":"BRIEF-Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464254","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642464254?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:08","pubTimestamp":1781003308,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System AtrophyJune 9 (Reuters) - Alterity Therapeutics Ltd ATH.AX:ALTERITY THERAPEUTICS A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498464","title":"Alterity Therapeutics - FDA Agrees to Phase 3 Design Including Umsars Part I as Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498464?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642464491","title":"Alterity Therapeutics - FDA Concurs With Ath434 50 Mg Twice Daily Dose for Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642464491?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346449","title":"Alterity Therapeutics - Phase 3 Trial Activities on Track to Initiate by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642346449?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642944437","title":"Alterity Therapeutics Ltd-Alterity and FDA Agree on Phase 3 Program for Ath434 in MSA-Ath","url":"https://stock-news.laohu8.com/highlight/detail?id=2642944437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642944437?lang=en_us&edition=fundamental","pubTime":"2026-06-09 07:01","pubTimestamp":1780959679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUE5HMYMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}